TF and acute myeloid leukemia: CONCLUSIONS: Targeted therapies in pediatric AML converge on ECM remodeling and a shared TF-driven regulatory axis, highlighting combinatorial strategies targeting microenvironmental and signaling vulnerabilities to overcome treatment resistance.